Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

Jesus García-Donas; Albert Font; Begoña Pérez-Valderrama; José Antonio Virizuela; Miquel Ángel Climent; Susana Hernando-Polo; José Ángel Arranz; Maria del Mar Llorente; Nuria Lainez; José Carlos Villa-Guzmán; Begoña Mellado; Aránzazu González del Alba; Daniel Castellano; Enrique Gallardo; Urbano Anido; Xavier García del Muro; Montserrat Domènech; Javier Puente; Rafael Morales-Barrera; Jose Luis Pérez-Gracia; Joaquim Bellmunt

doi:10.1016/s1470-2045(17)30242-5

Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30242-5 ◽

2017 ◽

Vol 18 (5) ◽

pp. 672-681a ◽

Cited By ~ 21

Author(s):

Jesus García-Donas ◽

Albert Font ◽

Begoña Pérez-Valderrama ◽

José Antonio Virizuela ◽

Miquel Ángel Climent ◽

...

Keyword(s):

Supportive Care ◽

Best Supportive Care ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Advanced Urothelial Carcinoma ◽

Randomised Controlled ◽

Line Chemotherapy

Download Full-text

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(20)30362-3 ◽

2021 ◽

Cited By ~ 2

Author(s):

Cornedine J de Gooijer ◽

Vincent van der Noort ◽

Jos A Stigt ◽

Paul Baas ◽

Bonne Biesma ◽

...

Keyword(s):

Malignant Mesothelioma ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Line Chemotherapy

Download Full-text

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

The Lancet Rheumatology ◽

10.1016/s2665-9913(20)30341-6 ◽

2020 ◽

Vol 2 (12) ◽

pp. e764-e773 ◽

Cited By ~ 9

Author(s):

Alexander P J Vlaar ◽

Sanne de Bruin ◽

Matthias Busch ◽

Sjoerd A M E G Timmermans ◽

Ingeborg E van Zeggeren ◽

...

Keyword(s):

Randomised Controlled Trial ◽

Supportive Care ◽

Controlled Trial ◽

Best Supportive Care ◽

Phase 2 ◽

Open Label ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text

Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2020.05.004 ◽

2020 ◽

Vol 18 (6) ◽

pp. 452-460

Author(s):

Joaquim Bellmunt Molins ◽

Jesús García-Donas Jiménez ◽

Begoña P. Valderrama ◽

Juan Antonio Virizuela Echaburu ◽

Susana Hernando-Polo ◽

...

Keyword(s):

Overall Survival ◽

Survival Analysis ◽

Supportive Care ◽

Urothelial Carcinoma ◽

Best Supportive Care ◽

Phase 2 ◽

First Line ◽

Advanced Urothelial Carcinoma ◽

Overall Survival Analysis ◽

Line Chemotherapy

Download Full-text

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)00075-9 ◽

2016 ◽

Vol 17 (5) ◽

pp. 632-641 ◽

Cited By ~ 49

Author(s):

Olivier Mir ◽

Claire Cropet ◽

Maud Toulmonde ◽

Axel Le Cesne ◽

Mathieu Molimard ◽

...

Keyword(s):

Supportive Care ◽

Best Supportive Care ◽

Phase 2 ◽

Gastrointestinal Stromal Tumours ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726282237.793552147 ◽

2018 ◽

Author(s):

Richard Riedel

Keyword(s):

Supportive Care ◽

Best Supportive Care ◽

Phase 2 ◽

Gastrointestinal Stromal Tumours ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Dose-Adjusted EPOCH Regimen as First-Line Treatment for Non-Hodgkin's Lymphoma with Hemophagocytic Lymphohistiocytosis: A Single-Arm, Open-Label, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3304299 ◽

2018 ◽

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hemophagocytic Lymphohistiocytosis ◽

Hodgkin's Lymphoma ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Non Hodgkin's Lymphoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)70098-7 ◽

2015 ◽

Vol 16 (4) ◽

pp. 406-416 ◽

Cited By ~ 97

Author(s):

Akira Kawai ◽

Nobuhito Araki ◽

Hideshi Sugiura ◽

Takafumi Ueda ◽

Tsukasa Yonemoto ◽

...

Keyword(s):

Supportive Care ◽

Best Supportive Care ◽

Phase 2 ◽

Standard Chemotherapy ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase

Download Full-text

Eltrombopag and Cyclosporine as First-Line Therapy in Patients with Severe Acquired Aplastic Anemia: A Two-part, 5-year, Single-Arm, Multicenter, Open-label, Phase 2 Trial (SOAR)

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2017.07.242 ◽

2017 ◽

Vol 17 ◽

pp. S389-S390

Author(s):

Phillip Scheinberg ◽

Joan Maier ◽

Ozlem Ocak Arikan ◽

Carlo Finelli ◽

Junho Jang

Keyword(s):

Aplastic Anemia ◽

Phase 2 ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Phase 2 Trial ◽

Line Therapy ◽

Open Label Phase

Download Full-text

Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(16)30234-4 ◽

2016 ◽

Vol 15 (12) ◽

pp. 1228-1237 ◽

Cited By ~ 147

Author(s):

Daniel F Hanley ◽

Richard E Thompson ◽

John Muschelli ◽

Michael Rosenblum ◽

Nichol McBee ◽

...

Keyword(s):

Minimally Invasive Surgery ◽

Minimally Invasive ◽

Invasive Surgery ◽

Intracerebral Haemorrhage ◽

Phase 2 ◽

Open Label ◽

Safety And Efficacy ◽

Phase 2 Trial ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text

Faculty Opinions recommendation of Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726858225.793557568 ◽

2019 ◽

Author(s):

Jose Biller

Keyword(s):

Minimally Invasive Surgery ◽

Minimally Invasive ◽

Invasive Surgery ◽

Intracerebral Haemorrhage ◽

Phase 2 ◽

Open Label ◽

Safety And Efficacy ◽

Phase 2 Trial ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text